GSK Bio

The Laboratory for Genomics Research will be funded by GSK up to $67 million over the five-year period and will include space for 24 full-time university employees and up to 14 full-time GSK staffers.

Yukin Therapeutics, a French company specializing in the development of new molecules for cancer treatment, has completed a €3.3 million financing round for the development and optimization of its proprietary therapeutic molecules.

Orchard Therapeutics, Fondazione Telethon and Ospedale San Raffaele announced that Orchard has been granted an exclusive worldwide license to intellectual property rights to research, develop, manufacture and commercialize the ex vivo autologous hematopoietic stem cell (HSC) gene therapy program for the treatment of Mucopolysaccharidosis Type I (MPS-I) developed by the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.

Orchard sees the gene therapy acquired as a potential treatment to “fundamentally change the lives of patients” who are born with this debilitating condition.

Appointment of Mr Vince Ippolito, a US-based dermatology industry leader with over 30 years of pharmaceuticals experience as President of Botanix

The company took its GSK-3B inhibitor into the clinic earlier this year. The drug is being studied in patients with refractory hematologic malignancies or solid tumors.

Biopharma companies add new leaders to executive roles and boards of directors.

The move by Vertex is part of the company’s plan to diversify its drug discovery strategies.

Pharma and biotech companies strengthen their leadership teams with new hires at Immunocore, Eisai, Kyn, Bicycle, and more.